ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PRV Porvair Plc

676.00
2.00 (0.30%)
18 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Porvair Plc LSE:PRV London Ordinary Share GB0006963689 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 0.30% 676.00 676.00 680.00 678.00 652.00 652.00 17,034 16:35:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 176.01M 15.97M 0.3445 19.51 311.48M
Porvair Plc is listed in the Chemicals & Chem Preps sector of the London Stock Exchange with ticker PRV. The last closing price for Porvair was 674p. Over the last year, Porvair shares have traded in a share price range of 522.00p to 738.00p.

Porvair currently has 46,351,837 shares in issue. The market capitalisation of Porvair is £311.48 million. Porvair has a price to earnings ratio (PE ratio) of 19.51.

Porvair Share Discussion Threads

Showing 1576 to 1599 of 1625 messages
Chat Pages: 65  64  63  62  61  60  59  58  57  56  55  54  Older
DateSubjectAuthorDiscuss
30/1/2023
18:17
Very solid results in my view. Always been a good generator of cash. Some caution comment going into 2023 seemed to unsettle the market, but year end order book at record levels and there is some history of under promising/over delivering. Always dyor.
partridge1948
10/1/2023
15:58
Taken a few more. Looks cheap under £6 imv
battlebus2
09/12/2022
11:52
Porvair Plc issued a pre-close trading update for the year ended 30th November this morning. Revenue for is expected to be 18% higher than 2021 on a reported basis (13% at constant currency) with all three divisions ahead and margins sustained. Adjusted earnings per share are expected to be ahead of market forecasts – current market consensus is for EPS 27.8p – so there will be double digit EPS growth. The balance sheet remains strong with net cash at year end of £18.1 million. The outlook also looks solid with order books going into 2023 healthy and lead times returning to more normal levels. Valuation is a little unhelpful with forward PE ratio up near 19x and 3rd quartile for the Machinery, Equipment & Components sector. The share price also lacked some near-term momentum prior to today’s spike. PRV has steady growth and decent profitability, but it is a share to monitor for now...

...from WealthOracle

kalai1
09/12/2022
11:09
I have held for 20 years! Well run and in my view tend to under promise/over deliver. Always thought one day it would fall to US predator, but always dyor.
partridge1948
09/12/2022
10:25
New buy for me this morning. 🤞
battlebus2
04/10/2022
11:39
Also several large trades at 515p this morning, beginning shortly after opening, well over 2% of the company if my maths is correct.
partridge1948
04/10/2022
08:18
Positive news this morning although odd timing - an 'ahead' statement 3 weeks after an 'inline' statement.
gleach23
13/9/2022
13:16
As a manufacturer, PRV 9 month trading update reads well to me. They look to be coping admirably with the various challenges currently being faced, with all divisions performing well. Historic tendency to under promise and over deliver I hope will be maintained. Always dyor.
partridge1948
06/7/2022
08:46
Solid half year results, maintaining good cash generation and decent profitability."Provided economic conditions allow, the outlook for the balance of the year is promising".Always dyor.
partridge1948
03/5/2022
15:04
Porvair comprises departments manufacturing filtration and separation equipment in the UK. The firm is segmented into three business areas: Aerospace & Industrial, Laboratory and Metal Melt Quality. The Aerospace & Industrial segment is focused on designing and manufacturing a range of specialist filtration equipment for aerospace, energy and industrial applications. Subsequently, the laboratory segment is engaged in the design and manufacture of instruments and consumables for use in biosciences laboratories. Furthermore, the Metal Melt Quality segment is specialised in designing and manufacturing porous ceramic filters for the filtration of molten metals. Given the diversified funding structure on designs and manufacturing, the firm generated multiples sources of income, which in turn forced up revenue by 14%. As a result, EV/EBITDA was driven up to 14.08x, capturing intrinsic value. Considering the revenue hike, the firm simultaneously managed to optimise its free cashflow, illustrated by the solid and robust P/FCF of 21.2x. Consequently, it implies that the firm is expected to enhance organic growth in 2022, displayed by the P/B ratio of 2.5x. Furthermore, Porvair derived a robust Return on Equity of 11.5%, signifying that both operating and investing activities are effectively funded by the firm to continue as a going concern while boosting the value of their portfolio.
km18
05/2/2022
10:10
To be fair, CEO has been there since 1998 and still owns over 500,000 shares.
partridge1948
04/2/2022
18:20
Not so nice to see CEO selling a chunk, notified at 3 p,m, on Friday
partridge1948
03/2/2022
14:02
And nice to see new FD buying a few. Been there long enough to get to know the business.
partridge1948
31/1/2022
18:23
Decent results and promising outlook, supported by improving picture in the aerospace division as air traffic hopefully recovers post covid-19.
partridge1948
13/7/2021
13:44
AGM statement reflected in half year numbers. Lab division boosted by covid related orders helping to offset aerospace shortfall and recent acquisition Kbiosystems looks imo to have been at a decent price.Always dyor
partridge1948
02/5/2021
12:06
Cautiously optimistic tone to the AGM statement recently seems to have been well received. Aerospace still subdued,albeit with early signs of better things to come, but other areas improving/going strongly.
partridge1948
10/3/2021
13:10
presumably a false rumour this morning caused the spike? ..but good to see 20p of spike not given back
25october1969
01/2/2021
11:39
Don't think results were that bad considering. I'd hope that the worse is behind them and that 2021 should see a recovery in the share price.
trickyricky
01/2/2021
11:06
Results about what was expected. At least orders have been steadily recovering from the nadir in July and cash generation remains solid. Shame that release of warranty provisions taken up by exceptional costs. I hold a little less uneasily than of late, but always dyor.
partridge1948
08/12/2020
13:06
Year end update about what might reasonably have been expected. Revenues only down 7% yoy, so could have been worse. Took action to cut costs as orders in Aerospace and Industrial/Metal melt shrank mid year,so some hefty exceptionals in the full year numbers. Profitable on a monthly basis and cash fine. Higher margin Laboratory side strong and some recovery being seen in other sectors, so perhaps better news in 2021. As a long term holder, I hope so!
partridge1948
10/11/2020
13:39
Two large deals gone through today at 547p (2 x 250,000 shares) so looks like someone has confidence. Year end is 30th Nov, so update due in the next month. As a long term holder I am sorry to see the FD relinquish full time duties(but staying as company secretary part time). Await the update rather nervously, but lab work should have meant they stayed profitable on a monthly basis, despite covid impact on aerospace/automotive and vaccine news might help those sectors in 2021. Also likely that lower working capital may have released some cash. Always dyor.
partridge1948
22/9/2020
19:12
Only caveat to this is that Laboratory division has higher margins than Aerospace & Industrial and Metal Melt Quality divisions, according to FY19 results segment info. (15.2% vs 12.7% and 7%). So maybe drop in rev offset by mix.
ottrott
22/9/2020
18:46
Thanks vprt. I do subscribe to Stockopedia and have not checked Paul Scott's maths, but I was expecting a sharp decline in Q3 revenues, so suspect he is not far from the truth. Quality business, but sidelines probably the best place at the moment, until aviation market in particular shows signs of recovery.
partridge1948
22/9/2020
16:57
Thanks for the comment partridge1948. If you are a Stockopedia subscriber I suggest you read Paul Scott's piece on this in the SCVR today. I am not going to copy and paste it here, but one point is that given the actual 1H numbers, using 9 months YTD seems to try to camouflage poor Q3 revenues; his rough estimate is sales down ca 12% on Q3 last year.

The lack of quantification or comment on profit or performance relative to expectations makes it a not particularly helpful update. I remain on the sidelines, expecting aviation exposure to remain painful also in 2021.

vprt
Chat Pages: 65  64  63  62  61  60  59  58  57  56  55  54  Older

Your Recent History

Delayed Upgrade Clock